View our Privacy Policy & Terms of Use
This free content is available to registered users.
Becoming a Registered User only requires your name and email address.
Does the Reparixin (CXCR1/2 Inhibitor) Improve Islet Cell Engraftment and Clinical Outcomes after Pancreatic Islet Allotransplantation in Patients with Type 1 Diabetes Mellitus? A Randomized, Double-Blind, Prospective Study
Speaker: Piotr J Bachul
Session: Islet and Pancreas Transplantation
Congress: 79th Scientific Sessions